- Trials with a EudraCT protocol (333)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
333 result(s) found for: Acute Phase Protein.
Displaying page 1 of 17.
EudraCT Number: 2007-000273-35 | Sponsor Protocol Number: 2/2007/U/Sper | Start Date*: 2007-03-22 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: A Phase II, Open-Label, Multi-centre, 2-part study to assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Newly Diagnosed Acute Myeloid Leukemia AML ... | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004968-40 | Sponsor Protocol Number: TUD-SORAML-034 | Start Date*: 2009-02-20 | |||||||||||
Sponsor Name:Technische Universität Dresden | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age | |||||||||||||
Medical condition: Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002365-37 | Sponsor Protocol Number: 3066K1-1165 | Start Date*: 2012-04-04 | |||||||||||
Sponsor Name:J.W. Goethe-University | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of temsirolimus added to standard primary therapy in elderly patients with newly diagnosed AML | |||||||||||||
Medical condition: Patients with newly diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS and AML after previous cytotoxic therapy or radiation (secondary AML) Bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001086-41 | Sponsor Protocol Number: UKM10_0014 | Start Date*: 2012-02-28 | |||||||||||
Sponsor Name:University Hospital of Muenster | |||||||||||||
Full Title: A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an in... | |||||||||||||
Medical condition: untreated acute myeloid leukemia patients unfit for an intensive treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004050-16 | Sponsor Protocol Number: HEAT-AML | Start Date*: 2019-08-01 | |||||||||||
Sponsor Name:University Hospital Karolinska | |||||||||||||
Full Title: HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A phase I/II multicenter study to assess the tolerability and efficacy of the addition of hydroxyurea to standard a... | |||||||||||||
Medical condition: Newly diagnosed acute myeloid leukaemia (AML) in patients ≥ 18 years of age | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000479-28 | Sponsor Protocol Number: LTS13932 | Start Date*: 2015-08-17 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase II Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia | |||||||||||||
Medical condition: Acute Myeloid Leukemia NOS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004527-35 | Sponsor Protocol Number: BIOV-121 | Start Date*: 2005-05-06 | |||||||||||
Sponsor Name:Bioenvision Limited | |||||||||||||
Full Title: A PHASE II TRIAL OF CLOFARABINE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA FOR WHOM INTENSIVE CHEMOTHERAPY IS NOT CONSIDERED SUITABLE | |||||||||||||
Medical condition: Acute Myeloid Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004282-15 | Sponsor Protocol Number: C1 1304-01 | Start Date*: 2005-06-22 | |||||||||||
Sponsor Name:PHARMING TECHNOLOGIES B.V. | |||||||||||||
Full Title: A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema | |||||||||||||
Medical condition: hereditary angioedema (HAE) treatment | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005107-42 | Sponsor Protocol Number: GIMEMA LAL1205 | Start Date*: 2006-09-29 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO | |||||||||||||
Full Title: A Phase II Multicenter Study on the Treatment of Adult de novo Philadelphia Chromosome Positive Ph Acute Lymphoblastic Leukemia ALL with the Protein Tyrosine Kinase Inhibitor BMS-354825. | |||||||||||||
Medical condition: Treatment of Adult de novo Philadelphia Chromosome Positive Ph Acute Lymphoblastic Leukemia ALL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005442-23 | Sponsor Protocol Number: 411-LY-08-01-0000 | Start Date*: 2009-02-19 | ||||||||||||||||
Sponsor Name:Leyh Pharma GmbH | ||||||||||||||||||
Full Title: Evaluation of the efficacy and safety of nose spray containing 3% silver protein diacetyl tannate (SEAT) in patients with uncomplicated viral rhinitis. A placebo-controlled, randomized, multicentri... | ||||||||||||||||||
Medical condition: treatment of uncomplicated rhinal infections | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003877-48 | Sponsor Protocol Number: TAK-662-1501 | Start Date*: 2022-12-21 | |||||||||||
Sponsor Name:Takeda | |||||||||||||
Full Title: An Open-Label, Single-Dose, Phase 1/2 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Human Protein C (TAK-662) for the Treatment of Congenital Protein C Deficiency in Japanese ... | |||||||||||||
Medical condition: Congenital Protein C Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023584-17 | Sponsor Protocol Number: RAS-AZIC | Start Date*: 2012-08-31 | |||||||||||
Sponsor Name:Universität Leipzig | |||||||||||||
Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent... | |||||||||||||
Medical condition: acute myeloid leukeamia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005159-14 | Sponsor Protocol Number: GC P#02.01.001 | Start Date*: 2008-04-15 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Gamida Cell-Teva Joint Venture Ltd. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in ... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: High-risk haematological malignancies (including AML, ALL, CML, NHL, HD, and MDS) with an indication for allogeneic haematopoietic stem cell transplantation, to support haematopoietic reconstitutio... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Completed) IT (Completed) HU (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003006-32 | Sponsor Protocol Number: ALL2418 | Start Date*: 2019-07-08 | ||||||||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | ||||||||||||||||||
Full Title: "A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hemato... | ||||||||||||||||||
Medical condition: Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000068-27 | Sponsor Protocol Number: XEN/TG-001 | Start Date*: 2013-11-29 | |||||||||||
Sponsor Name:Xenikos BV | |||||||||||||
Full Title: A Phase Ib/IIa multicentric study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for the treatment of steroid-resistant acute Graft-vers... | |||||||||||||
Medical condition: Acute Graft-versus-Host Disease (GVHD) not responding on regular first line therapy of 2 mg/kg corticosteroids daily. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003109-73 | Sponsor Protocol Number: TL-895-203 | Start Date*: 2021-02-15 | |||||||||||
Sponsor Name:Telios Pharma, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML) | |||||||||||||
Medical condition: Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023611-34 | Sponsor Protocol Number: NLCER-001-CLIN-002 | Start Date*: 2011-05-18 | ||||||||||||||||
Sponsor Name:Cerenis Therapeutics | ||||||||||||||||||
Full Title: A Phase II Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects with Acute Coronary Syndrome | ||||||||||||||||||
Medical condition: Symptoms of Acute Coronary Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004270-43 | Sponsor Protocol Number: AIEOP-BFMALL2009 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel | |||||||||||||
Full Title: International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia | |||||||||||||
Medical condition: acute lymphoblastic leukemia in children and adolescents 1 to <18 years of age | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) AT (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002727-15 | Sponsor Protocol Number: 114174 | Start Date*: 2015-06-22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II, randomized, controlled, observer-blind study to evaluate the impact of two formulations of GlaxoSmithKline (GSK) Biologicals’ combined 10-valent pneumococcal polysaccharide and non-type... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for one-dose vaccination of healthy children between 2-4 years of age at the time of vaccination against Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae (H. ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000943-14 | Sponsor Protocol Number: OLT1177-05 | Start Date*: 2017-02-23 | |||||||||||
Sponsor Name:Olatec Therapeutics LLC | |||||||||||||
Full Title: A Phase 2 Single-Center, Proof-of-Concept Safety and Efficacy Study of Orally Administered OLT1177 Capsules with Successive, Result-Dependent Dose Adaptation in Subjects with an Acute Gout Flare | |||||||||||||
Medical condition: Acute gout flare | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.